Europe Manufacturing, Packaging & Detailing Market Research Reports - Data on Manufacturing, Packaging & Detailing in Europe page 1

Printer Format

Region:	All Regions > Europe
Category:	All Categories > Life Sciences > Pharmaceuticals > Manufacturing, Packaging & Detailing

(338 reports matching your criteria)

Intellinews - Romania Pharmaceutical Report - May 2013 6/8/2013 \| published by: Intellinews ... statistics and comments. This sector report is ideal to keep you abreast on recent company and industry news. Written by local professionals, it is a unique market and business intelligence analysis, tailored to save time ... \| read more...	$210.00
Italy Pharmaceuticals and Healthcare Report Q3 2013 6/5/2013 \| published by: Business Monitor International ... may encourage the enforcement of further cost-containment measures, which, together with theongoing public hospital debt situation, seriously hampers the country's attractiveness as a location inwhich to sell drugs, despite its favourable demographic characteristics. Headline Expenditure ... \| read more...	$1,295.00
Pharmaceutical And Healthcare Market In Poland 2013 6/1/2013 \| published by: PMR ... pharmaceutical and healthcare markets. The experienced analysts at PMR have kept close watch on these changes, observing events and collecting data that documents variations in sales values of various medications, the value of the hospital ... \| read more...	$2,660.00
Poland Pharmaceuticals and Healthcare Report Q3 2013 5/29/2013 \| published by: Business Monitor International ... shifted onto the Polish consumer, as theharsher reimbursement regime caused a rise in private contributions to prescription payments. We forecasta return to growth in 2013, driven by demand for hospitals and private consumption growth as ... \| read more...	$1,295.00
Croatia Pharmaceuticals and Healthcare Report Q3 2013 5/15/2013 \| published by: Business Monitor International ... thecountry's economy. The Croatian pharmaceutical market continues to pose a challenging environment todomestic and international drugmakers, but we believe EU accession will ease the regulatory burden aslegislation is harmonised with EU norms. In 2013 the ... \| read more...	$1,295.00
Chemical & Pharmaceutical Plant Construction in Belgium to 2017: Market Databook 5/13/2013 \| published by: Timetric ... chemical & pharmaceutical plants construction industry, including a breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition). The databook provides historical and forecast valuations of the industry using the ... \| read more...	$500.00
Chemical & Pharmaceutical Plant Construction in Greece to 2017: Market Databook 5/13/2013 \| published by: Timetric ... chemical & pharmaceutical plants construction industry, including a breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition). The databook provides historical and forecast valuations of the industry using the ... \| read more...	$500.00
Switzerland Pharmaceuticals and Healthcare Report Q2 2013 5/8/2013 \| published by: Business Monitor International ... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.58bn (US$7.02bn) in 2012 to CHF6.44bn (US$6.27bn) in 2013; -2.1% declinein ... \| read more...	$1,175.00
OTC Triptans in Norway 5/1/2013 \| published by: Euromonitor International ... live longer, and vitamins and dietary supplements are products which can help to prevent health problems and can increase consumers’ health. The wider availability of products in different channels made it easier for consumers to ... \| read more...	$900.00
Generic And Innovative Drugs Market In Central Europe 2013 5/1/2013 \| published by: PMR ... for these preparations have become especially complex due to varying conditions that exist in each individual country. For example, generics represent a larger share of the market in Poland than in Romania, Slovakia, the Czech ... \| read more...	$3,500.00
Belarus Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... of domestic drug demand, we note that currency devaluationwould have significantly increased the price of imported raw materials and manufacturing equipment. Atthe same time, the country’s political stance may potentially disrupt supplies of high-tech medicinescurrently ... \| read more...	$1,175.00
Lithuania Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... the overall potential earnings in the countryfor pharmaceutical companies. Nevertheless, niche areas, such as biopharmaceuticals, will remain ofinterest to foreign majors, also from the point of view of exports. Headline Expenditure Projections Pharmaceuticals: LTL1.74bn (US$647mn) ... \| read more...	$1,175.00
Czech Republic Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... agencies and blind bidding auctions drive prices down year-onyear. The open movement of goods and services in the European Union has given rise to an arbitrageopportunity for medicines, which certain businesses have exploited. While within ... \| read more...	$1,175.00
United Kingdom Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... over the five years to 2017, we project that themarket will decline in value terms, because of patent expirations and various cost-containment measuresthat include cost-effectiveness assessment of expensive treatments. Still, high per capita consumption ofpatented ... \| read more...	$1,175.00
Healthcare, Regulatory and Reimbursement Landscape - Belgium 4/22/2013 \| published by: GlobalData ... regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the ... \| read more...	$1,995.00
Pharmaceuticals in Spain: ISIC 2423 4/18/2013 \| published by: Euromonitor International ... at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing ... \| read more...	$600.00
OTC Triptans in Sweden 4/18/2013 \| published by: Euromonitor International ... driver of sales and value growth in 2012. Euromonitor International's OTC Triptans in Sweden report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest ... \| read more...	$900.00
Consumer Health in Sweden 4/18/2013 \| published by: Euromonitor International ... self-medication and the ageing Swedish population. However, the growth rate was slower than the CAGR for the review period. This is primarily due to increased price competition caused by the launch of private label brands ... \| read more...	$2,400.00
Consumer Health in Greece 4/17/2013 \| published by: Euromonitor International ... review period, with switches and price increases fuelling growth, this has not been the case for 2012. With prices remaining relatively stable and manufacturers abstaining from switches, value sales declined amidst the very unfavourable conditions ... \| read more...	$2,400.00
Serbia Pharmaceuticals and Healthcare Report Q2 2013 4/17/2013 \| published by: Business Monitor International ... consumption is also expected to rise. However, financial inefficiencies within the healthinsurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet itsobligations on time, leaving patients to pay for formerly ... \| read more...	$1,175.00
Moldova Pharmaceuticals and Healthcare Report Q2 2013 4/17/2013 \| published by: Business Monitor International ... than half of the country’s total healthcare expenditure. Despite the need for more services and treatments – Moldova’s population is ageing rapidly, partly dueto emigration of younger and more skilled workers – the need for ... \| read more...	$1,175.00
Spain Pharmaceuticals and Healthcare Report Q2 2013 4/17/2013 \| published by: Business Monitor International ... fordrugmakers selling their products in Spain. The success of the implemented policies may encourage theenforcement of further cost-containment measures, which, with the ongoing public hospital debt situation,seriously hampers the country's attractiveness as a location in ... \| read more...	$1,175.00
Consumer Health in Poland 4/11/2013 \| published by: Euromonitor International ... role of OTC medicines in preventing certain ailments. Manufacturers underpin the trend by running educational campaigns and introducing novelties on a regular basis, which help to arouse consumers’ interest and prompt purchases. Euromonitor International's Consumer ... \| read more...	$2,400.00
Bulgaria Pharmaceuticals and Healthcare Report Q2 2013 4/10/2013 \| published by: Business Monitor International ... parties to force thegovernment to mandate currently voluntary price discounts through legislation. The potentialintroduction of additional restrictive policies – on top of the implemented mark-up ceilings forwholesalers and manufacturers and the expansion of countries in ... \| read more...	$1,175.00
Estonia Pharmaceuticals and Healthcare Report Q2 2013 4/10/2013 \| published by: Business Monitor International ... oncologic burden on the state healthcaresystem, and, over the long term, growth is expected to be steady due to base effects. Nevertheless the sizeof the market will remain comparatively small. Headline Expenditure Projections Pharmaceuticals: EUR259mn ... \| read more...	$1,175.00

< prev 1 2 3 4 5 6 7 8 9 10 next >